These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6416294)

  • 1. Human C1 inhibitor: improved isolation and preliminary structural characterization.
    Harrison RA
    Biochemistry; 1983 Oct; 22(21):5001-7. PubMed ID: 6416294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor.
    Prograis LJ; Hammer CH; Katusha K; Frank MM
    J Immunol Methods; 1987 May; 99(1):113-22. PubMed ID: 3553333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose.
    Pilatte Y; Hammer CH; Frank MM; Fries LF
    J Immunol Methods; 1989 Jun; 120(1):37-43. PubMed ID: 2732474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of a proteinase inhibitor from bovine serum with C1-inhibitor activity.
    Van Nostrand WE; Cunningham DD
    Biochim Biophys Acta; 1987 Feb; 923(2):167-75. PubMed ID: 3814612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary structure of the reactive site of human C1-inhibitor.
    Salvesen GS; Catanese JJ; Kress LF; Travis J
    J Biol Chem; 1985 Feb; 260(4):2432-6. PubMed ID: 3919001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and circular-dichroism studies on the interaction between human C1-esterase inhibitor and C1s.
    Nilsson T; Sjöholm I; Wiman B
    Biochem J; 1983 Sep; 213(3):617-24. PubMed ID: 6604523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor J: isolation and characterization of a new polypeptide inhibitor of complement C1.
    Lopez-Trascasa M; Bing DH; Rivard M; Nicholson-Weller A
    J Biol Chem; 1989 Sep; 264(27):16214-21. PubMed ID: 2476439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1 inhibitor.
    Davis AE; Aulak KS; Zahedi K; Bissler JJ; Harrison RA
    Methods Enzymol; 1993; 223():97-120. PubMed ID: 8271970
    [No Abstract]   [Full Text] [Related]  

  • 9. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s.
    Prandini MH; Reboul A; Colomb MG
    Biochem J; 1986 Jul; 237(1):93-8. PubMed ID: 3099750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.
    Harpel PC; Hugli TE; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):605-11. PubMed ID: 123252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THE CARBOHYDRATE-POLYPEPTIDE LINKAGES, THE AMINO ACID SEQUENCES OF THE PEPTIDES ADJACENT TO SOME OF THESE BONDS, AND THE COMPOSITION AND SIZE OF THE CARBOHYDRATE UNITS OF ALPHA-1-ACID GLYCOPROTEIN.
    SATAKE M; OKUYAMA T; ISHIHARA K; SCHMID K
    Biochem J; 1965 Jun; 95(3):749-57. PubMed ID: 14342511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of carbohydrate chains of C1-inhibitor and of desialylated C1-inhibitor.
    Schoenberger OL
    FEBS Lett; 1992 Dec; 314(3):430-4. PubMed ID: 1468580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modification of an affinity procedure for purification of human C1- inhibitor that provides a homogeneous stable preparation.
    Donaldson VH; Falconieri MW
    J Immunol Methods; 1993 Jan; 157(1-2):101-4. PubMed ID: 8423351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization.
    Bock SC; Skriver K; Nielsen E; Thøgersen HC; Wiman B; Donaldson VH; Eddy RL; Marrinan J; Radziejewska E; Huber R
    Biochemistry; 1986 Jul; 25(15):4292-301. PubMed ID: 3756141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and composition of a novel gastrointestinal tumor-associated glycoprotein expressing sialylated lacto-N-fucopentaose II (CA 19-9).
    Klug TL; LeDonne NC; Greber TF; Zurawski VR
    Cancer Res; 1988 Mar; 48(6):1505-11. PubMed ID: 2449952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of bovine factor VII.
    Kisiel W; Davie EW
    Biochemistry; 1975 Nov; 14(22):4928-34. PubMed ID: 1182130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-endorphin-related peptides in the human pituitary. Isolation and characterization of major immunoreactive peptides, including the formerly unrecognized peptide beta-endorphin 1-18.
    Vuolteenaho O
    Acta Physiol Scand Suppl; 1984; 531():1-84. PubMed ID: 6091413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.
    Parad RB; Kramer J; Strunk RC; Rosen FS; Davis AE
    Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6786-90. PubMed ID: 2118657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1.
    Chesne S; Villiers CL; Arlaud GJ; Lacroix MB; Colomb MG
    Biochem J; 1982 Jan; 201(1):61-70. PubMed ID: 6282262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.